Largest biotech companies by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech companies ranked by total liabilities, at SGD 105.7B, ahead of Gilead Sciences (SGD 47B) and Biogen (SGD 14.4B). Figures as of 18 Nov 2026, 19:49 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSGD 105.7B
- Median
- SGD 907M
- Combined market value
- SGD 1.08T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SGD 105.7B | SGD 309.3B | SGD 571.87 | 3.18% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | SGD 47B | SGD 270.2B | SGD 217.87 | 0.80% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | SGD 14.4B | SGD 47.7B | SGD 322.50 | 0.31% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | SGD 4.8B | SGD 103.4B | SGD 255.60 | 4.18% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | SGD 4B | SGD 26.7B | SGD 107.68 | 1.63% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | SGD 3.2B | SGD 13.2B | SGD 63.97 | 0.31% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | SGD 3.2B | SGD 14.1B | SGD 124.01 | 0.18% up | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SGD 1.8B | SGD 21.3B | SGD 210.73 | 1.54% down | 20% up | ||
| 9 | argenxARGX · Health Care | SGD 1.8B | SGD 76.5B | SGD 1,216.95 | 0.43% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | SGD 1.3B | SGD 9.3B | SGD 8.71 | 7.91% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | SGD 1.1B | SGD 14.1B | SGD 220.99 | 5.64% up | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | SGD 932.9M | SGD 44.7B | SGD 206.88 | 1.41% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | SGD 881.1M | SGD 21.6B | SGD 88.43 | 0.09% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | SGD 617.2M | SGD 14.7B | SGD 93.88 | 0.21% up | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SGD 443M | SGD 5.1B | SGD 52.50 | 1.37% up | 21% down | ||
| 16 | VaxcytePCVX · Health Care | SGD 409.2M | SGD 11.9B | SGD 75.45 | 1.53% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | SGD 371.1M | SGD 5.9B | SGD 36.59 | 0.42% down | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | SGD 250.4M | SGD 8.2B | SGD 124.77 | 0.07% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | SGD 217.9M | SGD 10.3B | SGD 150.54 | 4.21% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | SGD 210.4M | SGD 13.3B | SGD 156.24 | 0.33% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | SGD 204.8M | SGD 7.5B | SGD 61.26 | 5.35% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | SGD 147.3M | SGD 12B | SGD 404.75 | 5.10% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | SGD 134.7M | SGD 8.9B | SGD 42.82 | 0.03% down | 43% up | ||
| 24 | CG OncologyCGON · Health Care | SGD 50.3M | SGD 9.2B | SGD 103.49 | 1.63% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2899 SGD).
Questions and answers
Which biotech companies rank first by total liabilities?
Amgen (SGD 105.7B), Gilead Sciences (SGD 47B) and Biogen (SGD 14.4B) are the top three of the 24 biotech companies ranked by total liabilities as of 18 Nov 2026, 19:49 UTC.
How many biotech companies are in this ranking?
24 are ranked by total liabilities.
What are these biotech companies worth together?
The 24 biotech companies ranked by total liabilities have a combined market value of SGD 1.08T as of 18 Nov 2026, 19:49 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.